Saturday, July 11, 2026

Drug profile · INN

hydromorphone

hydromorphone (DILAUDID) is a mu opioid receptor agonist. Associated with Lacuna Pharma Pty Ltd.

TGA: approved NMPA: clinical trials
Patents linked 0
Pipeline programs 57
News articles 0
Drug details — hydromorphone

Quick answer

hydromorphone (DILAUDID) is a mu opioid receptor agonist. Associated with Lacuna Pharma Pty Ltd.

Key facts

INN hydromorphone
Brand DILAUDID
Mechanism Mu opioid receptor agonist

Mechanism of action

Mu opioid receptor agonist

Approval history

Authority Status Date
TGA approved
NMPA clinical trials

Pipeline programs

  1. 1438-0011 Phase 3 · Boehringer Ingelheim · advanced or metastatic extrapulmonary neuroendocrine carcino
  2. 1438-0012 Phase 3 · Boehringer Ingelheim · small cell lung cancer
  3. 1479-0008 Phase 3 · Boehringer Ingelheim · non-squamous non-small cell lung cancer
  4. 2-mg Intravitreous Aflibercept Injection Phase 3 · Regeneron UK · Proliferative Diabetic Retinopathy
  5. 213410 Phase 3 · GSK Glaxo Smith · Lung Cancer, Non-Small Cell
  6. 22615 Phase 3 · Bayer · Advanced non-small cell lung cancer with HER2 (ERBB2) mutati
  7. AC220-168 Phase 3 · Daiichi Sankyo US · Acute myeloid leukemia
  8. AG881-C-004 Phase 3 · George Institute for · Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mu

Frequently asked questions

What is hydromorphone?

hydromorphone (DILAUDID) is a mu opioid receptor agonist. Associated with Lacuna Pharma Pty Ltd.

What is the brand name for hydromorphone?

DILAUDID is a marketed brand name for hydromorphone. Check FDA Drugs@FDA for the current US label holder and prescribing information.